FDA Approves CARBIDOPA-LEVODOPA — Advagen Pharma Ltd.,

**CARBIDOPA AND LEVODOPA** tablets have received FDA approval through the **Advagen Pharma Ltd.** ANDA, a move expected to intensify price competition within the generic Parkinson’s disease market. The entry of this new formulation is anticipated to drive down costs for brand-name treatments, likely prompting existing generic manufacturers to adjust pricing strategies to retain market share.